Terns Pharmaceuticals Inc
TERN37.770USD
+2.390+6.76%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
3.31BCap. mercado
PérdidaP/E TTM
Más Datos de Terns Pharmaceuticals Inc Compañía
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in pipeline includes TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic dysfunction-associated steatohepatitis (MASH). It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
Información de Terns Pharmaceuticals Inc
Símbolo de cotizaciónTERN
Nombre de la empresaTerns Pharmaceuticals Inc
Fecha de salida a bolsaFeb 05, 2021
Director ejecutivoBurroughs (Amy L)
Número de empleados59
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 05
Dirección1065 East Hillsdale Blvd., Suite 100
CiudadFOSTER CITY
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94404
Teléfono16505255535
Sitio Webhttps://ternspharma.com/
Símbolo de cotizaciónTERN
Fecha de salida a bolsaFeb 05, 2021
Director ejecutivoBurroughs (Amy L)
Ejecutivos de Terns Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. David Fellows
Mr. David Fellows
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
--
--
Ms. Hongbo Lu, Ph.D.
Ms. Hongbo Lu, Ph.D.
Independent Director
Independent Director
--
--
Ms. Jill M. Quigley, J.D.
Ms. Jill M. Quigley, J.D.
Independent Director
Independent Director
--
--
Dr. Radhika Tripuraneni, M.D.
Dr. Radhika Tripuraneni, M.D.
Independent Director
Independent Director
--
--
Dr. Emil T. Kuriakose, M.D.
Dr. Emil T. Kuriakose, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Amy L. Burroughs
Ms. Amy L. Burroughs
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Sun (Melita) Jung
Ms. Sun (Melita) Jung
Chief Business Officer
Chief Business Officer
--
--
Ms. Heather D. Turner, J.D.
Ms. Heather D. Turner, J.D.
Independent Director
Independent Director
--
--
Mr. Robert W. (Bob) Azelby
Mr. Robert W. (Bob) Azelby
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. David Fellows
Mr. David Fellows
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
--
--
Ms. Hongbo Lu, Ph.D.
Ms. Hongbo Lu, Ph.D.
Independent Director
Independent Director
--
--
Ms. Jill M. Quigley, J.D.
Ms. Jill M. Quigley, J.D.
Independent Director
Independent Director
--
--
Dr. Radhika Tripuraneni, M.D.
Dr. Radhika Tripuraneni, M.D.
Independent Director
Independent Director
--
--
Dr. Emil T. Kuriakose, M.D.
Dr. Emil T. Kuriakose, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: sáb., 7 de feb
Actualizado: sáb., 7 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Soleus Capital Management, L.P.
7.65%
Morgan Stanley & Co. LLC
7.10%
Deep Track Capital LP
7.06%
Vivo Capital, LLC
6.49%
Commodore Capital LP
5.37%
Otro
66.33%
Accionistas
Accionistas
Proporción
Soleus Capital Management, L.P.
7.65%
Morgan Stanley & Co. LLC
7.10%
Deep Track Capital LP
7.06%
Vivo Capital, LLC
6.49%
Commodore Capital LP
5.37%
Otro
66.33%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
32.35%
Investment Advisor
20.53%
Investment Advisor/Hedge Fund
14.70%
Research Firm
8.39%
Venture Capital
6.62%
Private Equity
3.70%
Sovereign Wealth Fund
0.74%
Individual Investor
0.60%
Bank and Trust
0.15%
Otro
12.22%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
369
91.63M
86.28%
-20.76M
2025Q3
346
91.95M
105.09%
-23.09M
2025Q2
344
88.08M
100.66%
-23.35M
2025Q1
352
90.67M
103.82%
-24.88M
2024Q4
339
91.95M
108.28%
-13.40M
2024Q3
310
84.11M
100.51%
-7.48M
2024Q2
277
70.14M
99.60%
-17.86M
2024Q1
253
68.60M
105.57%
-10.37M
2023Q4
237
68.12M
109.36%
-7.25M
2023Q3
218
65.97M
109.78%
-9.89M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Soleus Capital Management, L.P.
8.13M
7.65%
-40.00K
-0.49%
Sep 30, 2025
Morgan Stanley & Co. LLC
7.54M
7.1%
+1.28M
+20.40%
Sep 30, 2025
Deep Track Capital LP
7.50M
7.06%
--
--
Sep 30, 2025
Vivo Capital, LLC
6.90M
6.49%
--
--
Sep 30, 2025
Commodore Capital LP
5.70M
5.37%
+5.70M
--
Sep 30, 2025
The Vanguard Group, Inc.
4.56M
4.29%
+253.75K
+5.89%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
5.04M
4.74%
+59.07K
+1.19%
Sep 30, 2025
Adage Capital Management, L.P.
3.94M
3.71%
+2.66M
+207.73%
Sep 30, 2025
OrbiMed Advisors, LLC
3.93M
3.7%
-3.63M
-48.04%
Nov 05, 2025
Candriam Belgium S.A.
2.37M
2.23%
--
--
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Roundhill GLP-1 & Weight Loss ETF
2.84%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.44%
Virtus LifeSci Biotech Clinical Trials ETF
1.42%
State Street SPDR S&P Pharmaceuticals ETF
0.83%
Tema Oncology ETF
0.52%
Invesco Dorsey Wright SmallCap Momentum ETF
0.39%
ALPS Medical Breakthroughs ETF
0.3%
ProShares Ultra Nasdaq Biotechnology
0.3%
iShares Russell 2000 Value ETF
0.13%
iShares Micro-Cap ETF
0.11%
Ver más
Roundhill GLP-1 & Weight Loss ETF
Proporción2.84%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporción2.44%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción1.42%
State Street SPDR S&P Pharmaceuticals ETF
Proporción0.83%
Tema Oncology ETF
Proporción0.52%
Invesco Dorsey Wright SmallCap Momentum ETF
Proporción0.39%
ALPS Medical Breakthroughs ETF
Proporción0.3%
ProShares Ultra Nasdaq Biotechnology
Proporción0.3%
iShares Russell 2000 Value ETF
Proporción0.13%
iShares Micro-Cap ETF
Proporción0.11%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
